Company Profile
Rocket Pharmaceuticals Stock Price, News & Catalysts
- Ticker:
- RCKT
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
3.50 USD (+0.57%)
Close
Last updated: September 17, 2026
316M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, RCKT closed up 0.57% at $3.50. No new same-company headline was identified in the current news window.
Company overview
Gene Therapies for Rare Disease
Rocket Pharmaceuticals develops gene therapies for rare hematologic and cardiovascular disorders using lentiviral and adeno-associated-virus vectors.
Commercial Hematology Franchise
KRESLADI is an ex vivo lentiviral gene therapy approved for severe leukocyte adhesion deficiency type I. It represents Rocket's first commercial product.
RP-A501
RP-A501 is an AAV gene therapy in pivotal Phase 2 development for Danon disease, a severe inherited cardiomyopathy caused by mutations in the LAMP2 gene.
RP-A701
RP-A701 is an AAV gene therapy for BAG3-related dilated cardiomyopathy and is preparing to enter first-in-human testing.
Future catalysts
- Regulatory update on a potential pivotal RP-A601 study in PKP2-associated arrhythmogenic cardiomyopathy in the second half of 2026.
- Initial patient dosing in the Phase 1 RP-A701 study for BAG3-associated dilated cardiomyopathy in the second half of 2026.
- Commercial availability and initial patient onboarding for KRESLADI in the fourth quarter of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Rocket Pharmaceuticals (RCKT)?
Rocket Pharmaceuticals (RCKT) most recently closed at 3.50 USD, a +0.57% move versus the previous session.
What is the market cap of Rocket Pharmaceuticals (RCKT)?
Rocket Pharmaceuticals currently has a market capitalization of 316M USD on BioPharmSignal.
What does Rocket Pharmaceuticals do?
Gene Therapies for Rare Disease Rocket Pharmaceuticals develops gene therapies for rare hematologic and cardiovascular disorders using lentiviral and adeno-associated-virus vectors. Commercial Hematology Franchise KRESLADI is an ex vivo lentiviral gene therapy approved for severe leukocyte adhesion deficiency type I. It represents Rocket's first commercial...
On which exchange is RCKT stock listed?
Rocket Pharmaceuticals (RCKT) is associated with NASDAQ, United States, Biopharma.
What is RP-A501?
RP-A501 RP-A501 is an AAV gene therapy in pivotal Phase 2 development for Danon disease, a severe inherited cardiomyopathy caused by mutations in the LAMP2 gene.
Which conditions is Rocket Pharmaceuticals targeting with RP-A501?
Rocket Pharmaceuticals is associated with rare disease, cardiovascular disease, hematology based on its company overview and current catalyst commentary.
How does Rocket Pharmaceuticals describe recent progress with RP-A501?
Regulatory update on a potential pivotal RP-A601 study in PKP2-associated arrhythmogenic cardiomyopathy in the second half of 2026. Initial patient dosing in the Phase 1 RP-A701 study for BAG3-associated dilated cardiomyopathy in the second half of 2026. Commercial availability and initial patient onboarding for KRESLADI in the fourth quarter of 2026.
What is RP-A701?
RP-A701 RP-A701 is an AAV gene therapy for BAG3-related dilated cardiomyopathy and is preparing to enter first-in-human testing.